In a woman over 60 with vaginal dryness, what alternatives to Sandrenal gel (vaginal estrogen gel) would you recommend?

Alternative Treatments to Vaginal Estrogen Gel for Vaginal Dryness in Women Over 60

For a woman over 60 with vaginal dryness who cannot or prefers not to use vaginal estrogen gel, I recommend starting with vaginal DHEA (dehydroepiandrosterone) as the first-line hormonal alternative, or vaginal moisturizers (polycarbophil-based or hyaluronic acid-based) used at least twice weekly as the first-line non-hormonal option. 1

Hormonal Alternatives (If Hormones Are Acceptable)

Vaginal DHEA (Prasterone)

• This is your best hormonal alternative to vaginal estrogen gel 1
• Provides statistically significant improvements in vulvovaginal dryness and dyspareunia compared to placebo
• Also improves sexual function, decreases vaginal pH, and improves vaginal epithelial anatomy
• Applied intravaginally, typically daily
• Has a Moderate Recommendation from the 2025 AUA/SUFU/AUGS guidelines 1

Oral Ospemifene (SERM)

• A selective estrogen receptor modulator taken orally (60 mg daily)
• May improve vulvovaginal dryness and dyspareunia 1
• Important caveats: Carries a boxed warning for endometrial thickening, increased stroke risk, and deep vein thrombosis risk 1
• Given these safety concerns, this should be a second-line option after DHEA
• Has only a Conditional Recommendation from guidelines 1

Non-Hormonal Options (If All Hormones Are Contraindicated or Refused)

Vaginal Moisturizers (First-Line Non-Hormonal)

Start here if the patient wants to avoid all hormones 2

• Polycarbophil-based moisturizers: Form a bioadhesive film on vaginal epithelium
• Hyaluronic acid-based preparations: Provide hydration and tissue support
• Dosing: Apply at least twice weekly (not just before intercourse) 2
• Onset: Provide symptom relief within days to weeks, though less effective than hormonal options 2
• Evidence: Recent 2024 RCT showed polycarbophil is non-inferior to hyaluronic acid, with both improving vaginal health index significantly 3
• Another 2024 study showed hyaluronic acid was comparable to vaginal estrogen for GSM symptoms 4

Vaginal Lubricants (Adjunctive Therapy)

• Use in addition to moisturizers, not as replacement 2
• Apply 15 minutes before sexual activity
• Options include water-based, silicone-based, or even olive oil 2
• Avoid petroleum jelly - associated with increased bacterial vaginosis risk 2
• These only provide temporary relief during intercourse and don't treat underlying atrophy

Clinical Decision Algorithm

Step 1: Determine if hormones are acceptable

• If YES → Offer vaginal DHEA first (better safety profile than ospemifene)
• If patient cannot use vaginal products → Consider oral ospemifene (but counsel on thrombotic/stroke risks)

Step 2: If all hormones contraindicated or refused

• Start vaginal moisturizer (polycarbophil or hyaluronic acid) at least twice weekly
• Add vaginal lubricant for sexual activity as needed

Step 3: Reassess at 8-12 weeks

• If inadequate response to non-hormonal therapy → Reconsider hormonal options through shared decision-making
• The 2015 Endocrine Society guidelines note that non-hormonal options are "not likely as effective as vaginal ET" 2

Important Caveats

Why might Sandrenal gel be discontinued?

• Note: The FDA drug label provided 5 appears to be for a sunscreen product, not a vaginal estrogen gel. This suggests either a labeling error or the patient may be using the wrong product. Verify what "Sandrenal gel" actually is.

Special populations:

• History of breast or endometrial cancer: Even low-dose vaginal estrogen requires shared decision-making with oncology 2. DHEA and non-hormonal options become more important here.
• On aromatase inhibitors: Avoid all estrogen products; use vaginal DHEA or non-hormonal options only 2

Common pitfalls:

• Don't prescribe lubricants alone - they only work during intercourse and don't treat underlying atrophy
• Moisturizers must be used regularly (at least twice weekly), not just when symptomatic
• If using non-hormonal therapy, set realistic expectations: improvement occurs but may be less dramatic than with hormones 2, 6

The 2025 guidelines emphasize that choice should consider not just efficacy, but also patient preference, accessibility, dexterity, anatomy, and social support 1 - so discuss these practical factors when selecting among options.